ICAD Inc represents values of innovation, collaboration, and dedication to advanced medical imaging technology. With a strong corporate philosophy focused on enhancing patient care and improving clinical outcomes, ICAD Inc continually develops cutting-edge solutions for early cancer detection and radiation therapy. By combining their expertise in artificial intelligence and image analysis, ICAD Inc enables healthcare professionals to make more accurate diagnoses and tailor personalized treatment plans. With a commitment to continuous improvement and providing superior healthcare solutions, ICAD Inc has established itself as a trusted leader in the industry.

ICAD Inc is primarily present in the United States, with headquarters located in Nashua, New Hampshire. As a leading provider of advanced image analysis technology solutions for the healthcare industry, ICAD Inc serves customers across the United States and also has a strong presence in Europe, Asia, and other regions around the globe. With its innovative solutions and commitment to improving patient outcomes, ICAD Inc continues to expand its reach in healthcare markets worldwide.

ICAD Inc has achieved several significant milestones over the years. Some of these include the development of innovative and leading-edge solutions for advanced imaging in the healthcare industry. The company has also successfully launched its renowned ProFound AI platform, which provides invaluable assistance to radiologists in the early detection of breast cancer. Furthermore, ICAD Inc has consistently focused on expanding its global presence by forging strategic partnerships and collaborations with industry leaders. With a commitment to continuous research and development, ICAD Inc continues to revolutionize the field of medical imaging, ensuring improved patient outcomes and enhanced clinical workflows.

ICAD Inc is a renowned company that specializes in advanced image analysis and cancer detection technologies. With a rich history spanning several decades, ICAD Inc was founded in 1984 as a research and development firm focusing on computer-aided detection (CAD) tools for mammography. Over the years, the company expanded its portfolio, offering innovative solutions for various cancer types, including lung, colon, and prostate. With a commitment to improving patient outcomes, ICAD Inc remains at the forefront of cutting-edge medical advancements. Leveraging its expertise in artificial intelligence and machine learning, ICAD Inc continues to deliver state-of-the-art solutions for early cancer detection, contributing to the advancement of medical diagnostics.

The main competitors of ICAD Inc in the market include companies like Varian Medical Systems, Elekta AB, and Accuray Incorporated.

ICAD Inc is primarily active in the healthcare and technology industries.

ICAD Inc's business model primarily focuses on providing innovative medical solutions to enhance cancer detection and therapy planning. As a leading provider of advanced imaging and radiation therapy technologies, ICAD aims to deliver state-of-the-art solutions that enable healthcare professionals to accurately diagnose and treat patients. Their expertise lies in developing and commercializing computer-aided detection (CAD) and workflow solutions for medical imaging in specialties such as breast, lung, and colon health. With a mission to improve patient outcomes and healthcare efficiency, ICAD Inc strives to revolutionize cancer care through their cutting-edge technologies.

ICAD KGV ir -5,23.

ICAD KUV ir 1,72.

AlleAktien kvalitātes vērtējums ICAD ir 3/10.

gaidāmā ICAD apgrozījums ir 19,18 milj. USD.

gaidāmā ICAD peļņa ir -6,32 milj. USD.

ICAD Inc is a US-based company that has been operating in the field of medical imaging since 1984. The company's business model focuses on the development and manufacturing of advanced imaging products. ICAD offers two main product lines: iCADx and ProFound AI. iCADx is a specialized group of diagnostic products used in image analysis in radiology and brachytherapy. ProFound AI is a groundbreaking software platform specifically designed for the interpretation of digital breast tomosynthesis (DBT). The two product lines from ICAD allow doctors to obtain more accurate and faster diagnostic results. The iCADx brand offers a range of products for the treatment of breast, prostate, lung, bone, and other types of cancer. The range also includes equipment for brachytherapy, a form of radiation therapy where a radiation source is directly inserted into the body. ProFound AI is an artificial intelligence (AI)-based software platform specifically designed for breast imaging. The system uses state-of-the-art algorithms and image analysis functions to assist the doctor in the early detection and diagnosis of breast cancer. In addition, ICAD also offers professional services such as training, customer support, and technical support. These services are aimed at ensuring that the products are used optimally and achieve the highest quality of imaging and diagnosis. ICAD also operates in the research and development field. The company continuously invests in research and development to improve and further develop its products, in order to provide medical users with the best possible diagnostics. The company also actively collaborates with leading medical institutions, research organizations, and other companies to drive collaborative projects and innovation in the field of medical imaging. In conclusion, it can be said that ICAD's business model is based on state-of-the-art medical imaging technology that improves diagnosis in medical practice. ICAD aims to drive further growth and expansion of the company by constantly improving its technologies and introducing innovative products to the market.

ICAD izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt ICAD vai uzņēmums nedod dividendes.

ICAD ISIN ir US44934S2068.

ICAD WKN ir A1J20J.

ICAD simbols ir ICAD.

Pēdējo 12 mēnešu laikā ICAD maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos ICAD plāno maksāt dividendes 0 USD apmērā.

ICAD pašreizējā dividendu rentabilitāte ir .

ICAD maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

ICAD pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

ICAD tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu ICAD apmērā 0 USD, kas tika izmaksāta 13.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 13.07.2024..

Pēdējās dividendes izmaksa notika 13.07.2024..

Gadā 2023, ICAD izmaksāja 0 USD dividendes.

ICAD dividendes tiek izmaksātas USD.